Continuous disclosure obligations might not be definitive enough and maybe we are to assume that Tox studies have commenced but further to this, continuous disclosure obligations will need to be adhered to prior to, or at time of ann results thereof
Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier, page-82
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $3.875K | 553.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 3120846 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1568171 | 2 |
View Market Depth
| Last trade - 13.18pm 05/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |